We would love for you to become a part of our community. Join our Discord to connect with us and other members!

Ticker
FAGR.BR

Price
16.72
Stock movement up
+0.02 (0.12%)
Company name
Fagron NV
Exchange
(BR
,
Currency
EUR
)
Sector
Healthcare >
Drug Manufacturers - Specialty & Generic
Markedsværdi
1.22B
Ent værdi
1.69B
Pris/omsætning
1.02
Pris/bog
2.55
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
39.87%
Efterfølgende P/E
10.97
Fremtidig P/E
12.94
PEG
-
EPS-vekst
10.36%
1 års afkast
0.12%
3 års afkast
2.47%
5 års afkast
-4.25%
10 års afkast
-5.87%
Senest opdateret: 2024-12-28

UDBYTTE

FAGR.BR betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E10.97
Pris til OCF7.12
Pris til FCF12.01
Pris til EBITDA4.68
EV i forhold til EBITDA6.49

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning1.02
Pris til egenkapital2.55
EV i forhold til salg1.42

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier72.84M
EPS (TTM)1.52
FCF pr. aktie (TTM)1.39

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)1.19B
Bruttofortjeneste (TTM)246.81M
Driftsindkomst (TTM)173.29M
Nettoindkomst (TTM)110.97M
EPS (TTM)1.52
EPS (1 år frem)1.29

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)20.70%
Driftsmargin (TTM)14.53%
Fortjenstmargin (TTM)9.31%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter96.69M
Nettotilgodehavender86.62M
Omsætningsaktiver i alt348.24M
Goodwill448.22M
Immaterielle aktiver48.54M
Ejendomme, anlæg og udstyr0.00
Sum aktiver1.05B
Kreditor117.11M
Kortfristet/nuværende langsigtet gæld362.76M
Summen af kortfristede forpligtelser200.47M
Sum gæld567.95M
Aktionærernes egenkapital477.11M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)170.95M
Investeringsudgifter (TTM)69.55M
Fri pengestrøm (TTM)101.40M
Udbetalt udbytte (TTM)40.43M

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast23.26%
Afkast af aktiver10.62%
Afkast af investeret kapital23.19%
Kontant afkast af investeret kapital21.19%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning16.70
Daglig høj16.78
Daglig lav16.64
Daglig volumen65K
Højeste gennem alle tider41.63
1 års analytiker estimat22.24
Beta0.26
EPS (TTM)1.52
Udbytte pr. aktie-
Ex-div dato21 May 2024
Næste dato for resultatpræsentation13 Feb 2025

Nedsidepotensial

Loading...
Nedsidepotensial-data
FAGR.BRS&P500
Nuværende prisfald fra top notering-59.84%-2.11%
Højeste prisfald-90.66%-56.47%
Højeste efterår dato14 Dec 20159 Mar 2009
Gennemsnitlig fald fra toppen-40.50%-11.13%
Gennemsnitlig tid til nyt højdepunkt39 days12 days
Maks. tid til nyt højdepunkt2662 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
FAGR.BR (Fagron NV) company logo
Markedsværdi
1.22B
Markedsværdi kategori
Small-cap
Beskrivelse
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Personale
3647
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Belgium
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 23 Dec 2024 – 7AM CET Fagron updates on FDA communication regarding the June 2024 inspection at Wichita Follow...
23. december 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 November 2024 – 6.45 PM CET Disclosure of notification received from FMR LLC Pursuant to the Belgian law of 2 May 2007 regardin...
26. november 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...
10. oktober 2024
Fagron SA (ARSUF) reports robust revenue growth and improved margins, with significant gains in North America and an optimistic outlook for the full year.
9. oktober 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 8 October 2024 – 9:00 PM CET Disclosure of notification received from AOC Pharma S.à r.l. Pursuant to the Belgian law of 2 May 200...
8. oktober 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program to...
13. september 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 September 2024 – 6PM CET Fagron’s share buy-back program: Weekly update In the period from 2 September 2024 through 6 September 2...
6. september 2024
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 1 August 2024 – 7:00 AM CET Fagron delivers strong performance with 16% topline growth and 17% increase in REB...
1. august 2024
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 13 May 2024 – 7PM CET Fagron shareholders approve all voting items at AGM and EGM Fagron, the leading global player in pharmaceutic...
13. maj 2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 12 April 2024 – 8AM CET Fagron publishes agenda for 2024 annual shareholders meeting and extraordinary general meeting The Board o...
12. april 2024
Næste side